Astrazeneca (AZN) Other Accumulated Expenses (2009 - 2026)

Astrazeneca's Other Accumulated Expenses history runs 18 years deep, the most recent figure standing at -$2.2 billion for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 5.74% year-over-year to -$2.2 billion; the TTM figure through Mar 2026 stood at -$2.2 billion (down 5.74% YoY), while the FY2025 annual figure was -$2.4 billion, down 34.41% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at -$2.2 billion, up from -$2.4 billion in the prior quarter.
• The five-year high for Other Accumulated Expenses was -$1.6 billion in Q2 2025, with the low at -$4.9 billion in Q3 2022.
• The 5-year median for Other Accumulated Expenses is -$2.4 billion (2025), against an average of -$2.7 billion.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses surged 54.04% in 2023, then slumped 34.41% in 2025.
• Astrazeneca's Other Accumulated Expenses stood at -$4.3 billion in 2022, then jumped by 37.7% to -$2.7 billion in 2023, then soared by 33.46% to -$1.8 billion in 2024, then plunged by 34.41% to -$2.4 billion in 2025, then grew by 9.42% to -$2.2 billion in 2026.
• Business Quant data shows AZN's Other Accumulated Expenses at -$2.2 billion in Q1 2026, -$2.4 billion in Q4 2025, and -$2.0 billion in Q3 2025.